$NRIX mention timeline

Nurix Therapeutics. Every tracked FinTwit mention of $NRIX, newest first. 9 mentions since the first on Nov 19, 2025. See the price chart.

February 2026 · 1 mention

Feb 6
Jacob Plieth — If $ABBV BTK degrader ABBV-101 has been discontinued (Evercore ISI confirms to us that it has) that's good news for $ONC & $NRIX -> https://t.co/aF1sORkqDY↗

Jan 9
Jacob Plieth — Ascentage just disclosed that it's developing a BTK degrader: APG-3288 apparently just had its US IND cleared $ONC $NRIX↗

Dec 9
Jacob Plieth — If you enjoyed #ASH25 you can catch up on all @ApexOnco coverage, including previews, here -> https://t.co/XIQrEeKMwY $TERN $JNJ $LLY $CGEM $ONC $NRIX $PFE $REGN $KURA↗
Dec 9
Jacob Plieth — $LLY Jaypirca looks best... up to a point. Via @ApexOnco from #ASH25 https://t.co/SgHJrraNrI $ONC $AZN $JNJ $ABBV $NRIX↗
Dec 8
Jacob Plieth — $NRIX +23% surprises me. I thought the #ASH25 data showed $ONC to be better on efficacy (with caveats), albeit worse on safety. My earlier take on @ApexOnco -> https://t.co/rPlU…↗
Dec 8
Jacob Plieth — By my calculation $ONC now has an efficacy edge vs $NRIX in BTK degradation. Caveats: small pt numbers, X-trial comparison, and Nurix might have the safety advantage #ASH25 https:/…

Nov 19
Jacob Plieth — @DmitryKovalchuk TBH I've no idea why $NRIX is up. Sands' comments seemed fairly inconsequential.↗
Nov 19
Jacob Plieth — $NRIX bexobrutideg uses different formulations for autoimmune vs haem-onc. Handy for future pricing considerations! #Jefferies25↗
Nov 19
Jacob Plieth — $NRIX Arthur Sands: "We anticipate that $LLY Jaypirca will get full approval." Hence focus for AA of bexobrutideg is triple-exposed population #Jefferies25↗